Source: International Congress 2017 – ILDs: clinical aspects
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Lewandowska (Warszawa, Poland). Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry. 855

Member's Comments

No comment yet.

Related content which might interest you: Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland. Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Central European idiopathic pulmonary fibrosis (IPF) patients survey Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study. Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Clinical pattern of idiopathic pulmonary fibrosis in Iran: A retrospective study Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Prevalence of idiopathic pulmonary fibrosis in Japan and the US: a claims-based retrospective study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Lung function of idiopathic pulmonary fibrosis: Russian IPF registry (Moscow region) Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF) Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Bosentan in idiopathic pulmonary fibrosis (IPF) patients: the BUILD 1 study Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006 Post-marketing surveillance of pirfenidone for idiopathic pulmonary fibrosis in Japan: Interim analysis of 973 patients Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012